189 related articles for article (PubMed ID: 14688006)
1. Feasibility of idiotype vaccination in relapsed B-cell malignancies.
Inogés S; Rodríguez-Calvillo M; López-Díaz de Cerio A; Zabalegui N; Pérez-Calvo J; Panizo C; Hernandez M; Cuesta B; Rocha E; Bendandi M
Haematologica; 2003 Dec; 88(12):1438-40. PubMed ID: 14688006
[No Abstract] [Full Text] [Related]
2. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
4. The use of idiotype as a target for clinical immunotherapy of B cell malignancies.
Kim SB; Kwak LW
Cancer Chemother Biol Response Modif; 2001; 19():289-95. PubMed ID: 11686018
[No Abstract] [Full Text] [Related]
5. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines against haematological malignancies.
Stevenson FK; King CA; Spellerberg MB; Zhu D; Rice J; Sahota S; Thompsett A; Radl J; Hamblin TJ
Haematologica; 1999 Jun; 84 Suppl EHA-4():11-3. PubMed ID: 10907456
[TBL] [Abstract][Full Text] [Related]
7. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
[TBL] [Abstract][Full Text] [Related]
8. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
[TBL] [Abstract][Full Text] [Related]
9. Future of idiotypic vaccination for B-cell lymphoma.
de Cerio AL; Inogés S
Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
11. [Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].
Mellstedt H; Fagerberg J; Osterborg A
Lakartidningen; 1998 Mar; 95(13):1405-10. PubMed ID: 9560967
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for lymphomas: idiotype vaccines and beyond.
Houot R; Levy R
Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
[TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
Longo DL
J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
[No Abstract] [Full Text] [Related]
14. [Past, present and future of anti-idiotype vaccination].
Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M
Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921
[TBL] [Abstract][Full Text] [Related]
15. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial.
Thomas SK; Kwak LW
Semin Oncol; 2012 Jun; 39(3):253-62. PubMed ID: 22595048
[TBL] [Abstract][Full Text] [Related]
17. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
Timmerman JM
Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
[No Abstract] [Full Text] [Related]
19. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
20. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
